Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.47 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | TK1 | P04183 | 3/20 | 0.44 |
| ▸ | TK2 | O00142 | 1/20 | 0.43 |
| ▸ | PNP | P00491 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | POLA1 | P09884 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL889695 | 1.00 | ADRB1 (0.47) | ADRB1DNMT1LMNASMN1; SMN2TK1 | |
| SCHEMBL12123502 | 1.00 | ADRB1 (0.47) | ADRB1DNMT1LMNASMN1; SMN2TK1 | |
| SCHEMBL23786492 | 1.00 | ADRB1 (0.47) | ADRB1DNMT1LMNASMN1; SMN2TK1 | |
| SCHEMBL7663097 | 0.85 | DNMT1 (0.47) | ADRB1DNMT1LMNASMN1; SMN2TK1 | |
| SCHEMBL12541656 | 0.82 | ADRB1 (0.46) | ADRB1DNMT1LMNASMN1; SMN2TK1 | |
| SCHEMBL9205135 | 0.81 | TK1 (0.45) | ADRB1DNMT1LMNASMN1; SMN2TK1 | |
| SCHEMBL9205122 | 0.81 | TK1 (0.45) | ADRB1DNMT1LMNASMN1; SMN2TK1 | |
| SCHEMBL31753101 | 0.81 | POLB (0.56) | POLB | |
| SCHEMBL12650020 | 0.81 | ALDH1A1 (0.45) | LMNAPNP | |
| SCHEMBL6062703 | 0.81 | ADRB1 (0.45) | ADRB1DNMT1LMNASMN1; SMN2TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4733412-A2 | METHOD FOR IDENTIFYING A PREDETERMINED NUCLEOTIDE SEQUENCE | Bruker Spatial Biology, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-3794146-B1 | METHOD FOR IDENTIFYING A PREDETERMINED NUCLEOTIDE SEQUENCE | BRUKER SPATIAL BIOLOGY INC (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20250289846-A1 | METHODS OF PURIFYING ANTIBODY-NUCLEIC ACID CONJUGATES | BRUKER SPATIAL BIOLOGY, INC. | 2025-09-18 | — | — | US | disclosed |
| US-20250277263-A1 | CHEMICAL COMPOSITIONS AND METHODS OF USING SAME | BRUKER SPATIAL BIOLOGY, INC. | 2025-09-04 | — | — | US | disclosed |
| CN-112703255-B | Chemical compositions and methods of use thereof | 布鲁克空间生物学公司 | 2025-04-29 | — | — | CN | disclosed |
| US-12281356-B2 | Chemical compositions and methods of using same | BRUKER SPATIAL BIOLOGY, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| EP-4514960-A1 | METHODS OF PURIFYING ANTIBODY-NUCLEIC ACID CONJUGATES | Bruker Spatial Biology, Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| CN-119365595-A | Method for purifying antibody-nucleic acid conjugates | 布鲁克空间生物学公司 | 2025-01-24 | — | — | CN | disclosed |
| US-20240279723-A1 | COMPOSITIONS AND METHODS FOR IN SITU SINGLE CELL ANALYSIS USING ENZYMATIC NUCLEIC ACID EXTENSION | BRUKER SPATIAL BIOLOGY, INC. | 2024-08-22 | — | — | US | disclosed |
| EP-4168578-B1 | COMPOSITIONS AND METHODS FOR IN SITU SINGLE CELL ANALYSIS USING ENZYMATIC NUCLEIC ACID EXTENSION | BRUKER SPATIAL BIOLOGY INC (US) | 2024-08-07 | — | — | EP | disclosed |
| US-20230220461-A1 | CHEMICAL COMPOSITIONS AND METHODS OF USING SAME | BRUKER SPATIAL BIOLOGY, INC. | 2023-07-13 | — | — | US | disclosed |
| CN-116406428-A | Compositions and methods for in situ single cell analysis using enzymatic nucleic acid extension | 纳米线科技公司 | 2023-07-07 | — | — | CN | disclosed |
| EP-4168578-A1 | COMPOSITIONS AND METHODS FOR IN SITU SINGLE CELL ANALYSIS USING ENZYMATIC NUCLEIC ACID EXTENSION | Nanostring Technologies, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| US-11549139-B2 | Chemical compositions and methods of using same | NANOSTRING TECHNOLOGIES, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| WO-2022266416-A1 | COMPOSITIONS AND METHODS FOR IN SITU SINGLE CELL ANALYSIS USING ENZYMATIC NUCLEIC ACID EXTENSION | NANOSTRING TECHNOLOGIES, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| CN-112703255-A | Chemical compositions and methods of use thereof | 纳米线科技公司 | 2021-04-23 | — | — | CN | disclosed |
| EP-3794146-A1 | CHEMICAL COMPOSITIONS AND METHODS OF USING SAME | Nanostring Technologies, Inc. (US) | 2021-03-24 | — | — | EP | disclosed |
| US-20190345548-A1 | CHEMICAL COMPOSITIONS AND METHODS OF USING SAME | BRUKER SPATIAL BIOLOGY, INC. | 2019-11-14 | — | — | US | disclosed |
| US-20070060744-A1 | Process for the synthesis of pyrazolopyrimidines | EPOCH BIOSCIENCES, INC. (US) | 2007-03-15 | — | — | US | disclosed |
| US-20070060744-A1 | Process for the synthesis of pyrazolopyrimidines | EPOCH BIOSCIENCES, INC. (US) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060744-A1 | Process for the synthesis of pyrazolopyrimidines | DPYD, PNP, UMPS | ADRB1 4570/4885DNMT1 356/4885LMNA 4171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.